Phidiax Competitors

DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare.

PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!

CureMetrix is committed to the advancement of technology that improves disease detection and survival rates worldwide. Our AI-based products and research are focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Today, our powerful image analysis platform is an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their health. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs, and increased assurance that patients are getting the highest standard of care available from screening. Over the last 10 years since our founding in 2014, we have focused on building products with extremely high efficacy that are easy to install, operate within existing clinical workflows, and minimize extra steps from radiologists and patients. CureMetrix has partnered with practicing radiologists, cardiologists, and esteemed institutions around the world to collect over 5 million images to train and validate our algorithms. From breast cancer to heart disease to kidney disease we believe that AI can be used to improve outcomes for patients and extend the impact and value of screening programs globally.